
iStent inject [Image from Glaukos]
iStent inject W
Glaukos Corporation
Glaukos’s iStent inject is an eye implant designed for cataract surgery to reduce intraocular pressure in adults with mild-to-moderate primary open-angle glaucoma.
San Clemente, Calif.–based Glaukos designed the device with a pair of heparin-coated titanium stents in a pre-loaded auto-injection system that allows them to be injected into multiple trabecular meshwork locations through a single corneal entry point. It creates two bypass pathways through the trabecular meshwork for a multi-directional flow through Schlemm’s canal.
The company won FDA premarket approval for iStent in June 2018 and was a nominee for Prix Galien’s best medical technology award in 2020.